The Impact of COVID-19 on Health Anxiety and Perceived Stress Among Persons with IBD: A Population-representative Study Authors: Seth R Shaffer, Gia L Jackson, Sydney Chochinov, Casandra Dolovich, Lesley A Graff, Renée El-Gabalawy, Souradet Yuh-Nan Shaw, Harminder Singh, Charles N Bernstein Published: 2023 ABSTRACT AbstractBackgroundThe Corona Virus Immune Disease-2019 (COVID-19) pandemic has broadly impacted the mental health of individuals worldwide, especially with restrictions including social distancing and quarantining. Persons with IBD are at increased risk of mental health disorders. The aim was to understand how the COVID-19 pandemic affected adults with a chronic health issue, inflammatory bowel disease (IBD), using a population-based sample.MethodsA survey study in Manitoba was conducted during the second COVID-19 wave in autumn 2020. We assessed proportions of health anxiety and perceived stress using validated measures, as well as stressors during the COVID-19 pandemic. We used univariable and multivariable logistic regression analysis to assess predictors of perceived stress and health anxiety.ResultsA total of 1,384 (47.1%) persons responded, with a mean age of 58.0, and 46.9% had Crohn’s disease. Almost three quarters (73.7%) had increased stress, with 37.7% having increased stress about their IBD, and 33.6% worried about their IBD worsening. 46.0% felt increased stress about accessing their doctor or nurse, and 56.5% felt they had good access to their gastroenterologist. Elevated stress and health anxiety were seen in 63.5% and 17.2% of respondents, respectively. Younger age and being on immune-modifying therapy (IMT) was predictive of increased health anxiety and stress. Longer IBD duration was associated with decreased stress, including those on IMT.ConclusionPersons with IBD reported high rates of stress and health anxiety early in the COVID-19 pandemic, especially among those on IMT. It will be important to determine how this evolved over time and to what extent this impacted on disease course.Keywords: COVID-19, IBD, mental health, survey study Introduction The Corona Virus Immune Disease-2019 (COVID-19) pandemic has globally impacted public health and the world economy. In the context of this worldwide pandemic, there have also been mental health sequelae, including escalating rates of anxiety and depression.1,2 For individuals with chronic disease or other health concerns, psychological distress is related, in part, to challenges in accessing medical care including procedures, hospitalizations, and/or surgeries that would have otherwise been warranted in their disease management.3 Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated inflammatory disease often requiring surgical and medication management. It is well established by our team and others that persons with IBD have significantly higher rates of depression and anxiety than the general population and that mental health symptoms exacerbate the disease.4–8 Given the strong relationship between mental and physical health in IBD, increased mental health challenges are anticipated to translate to worsening disease outcomes. An online survey in Australia of persons with IBD reported 34.9% and 32.0% of people without a prior mental health diagnosis exhibiting new symptoms of depression and anxiety, respectively.9 A US-based cross-sectional survey of persons with IBD found the majority had increased anxiety from early in the pandemic, which was associated with an increase in gastrointestinal symptoms.10 There is a need to identify the extent to which those with IBD experienced new mental health problems and had exacerbations of existing comorbid psychiatric conditions. This will help us understand how those with chronic diseases, such as IBD, have responded to the ongoing COVID-19 pandemic, and their changing care needs, in addition to guiding health system response for future pandemic waves or other public health crisis. While the mental health of persons with IBD has been studied throughout the COVID-19 pandemic, none of these have been population-based studies, nor have they assessed broader variables such as economic impact, health stressors, and access to the care team or specialist. Our aim was to determine the mental health impact of the COVID-19 pandemic on adults with IBD in Manitoba during the first year of the pandemic. Materials and methods This is a cross-sectional study whereby participants of the population-based University of Manitoba IBD Research Registry (UMIBDRR),11 (n = 2,940), where addresses are regularly being updated, were invited to participate in a survey regarding their experiences with COVID-19 during autumn 2020, just prior to and during the second pandemic wave in Manitoba. Approximately 45% of persons with IBD in Manitoba are enrolled in the UMIBDRR.7,12 This study was approved by the Research Ethics Board at the University of Manitoba. A letter of introduction, consent form, and paper survey were mailed to registry participants, inviting their participation and providing the option to complete the survey via the provided paper copy or by accessing an online link to complete the survey through the REDcap platform. Using a modified Dillman method13 we sent email or letter reminders, depending on available contact information, to complete the survey to those who had not responded at 2 and 4 weeks. If information was missing from a survey, we attempted to contact that respondent for their responses. Survey data were kept confidential as names were removed from responses once uploaded, and were only accessible by our statistician. Measures The survey included background sociodemographic and disease information (e.g., phenotype, medication use), employment status pre- and peri-pandemic including changes in hours and income, and questions regarding healthcare access and use, Mental health needs and access to care were assessed using the Canadian Community Health Survey (2018) questions, with validated measures of perceived stress scale (based on perceived stress scale-10)14 and health anxiety (based on short health anxiety inventory-14).15 This is included in the supplementary material. Outcomes and predictors We included two main predictors of mental health: health anxiety and perceived stress. Perceived stress was defined using the PSS-10 survey. A score of greater than 13 was indicative of elevated perceived stress. Health anxiety was defined using the SHAI-14 survey. A score of greater than 17 was positive for elevated health anxiety. Possible predictors of elevated perceived stress and elevated health anxiety included demographic and IBD-related variables such as age (17–64, 65+), disease diagnosis (CD vs. UC), disease duration of IBD in years (0–10, 1–30, 30+), use of any IBD-therapy, and use of any immune-modifying therapy (including corticosteroids, azathioprine/6-mercaptopurine, methotrexate, biologic therapy including infliximab, adalimumab, vedolizumab, ustekinumab, or tofacitinib). Pandemic-related predictor variables for stress and health anxiety included the presence of gastrointestinal symptoms, work-from-home status, the status of children at home, decreased work hours during the pandemic if the person was an essential worker, and if they were a frontline worker. We also describe relevant stressors persons with IBD experienced at this point in time of the pandemic across multiple dimensions, including their disease, access to therapy, or access to care. Statistical analysis Among survey respondents, we included people who were diagnosed with either CD or UC in the final analysis. Descriptive statistics were presented as means and standard deviations (SD), and percentages. Bivariate analysis was conducted for CD versus UC; persons with IPAA along with those who were unaware of their phenotype, were excluded from these analyses due to their small numbers. For bivariate analyses, we used the Student’s t test for continuous variables and Fisher’s exact and Chi-square tests for categorical variables, where appropriate. In order to assess the association between predictors of perceived stress and health anxiety, we used both univariate and multivariable logistic regression analysis. Multivariable models included COVID-19-related, demographic, and IBD-related variables (age, disease phenotype, disease duration, and being on immune-modifying therapies). A P value of <0.05 was considered to be statistically significant. All data analyses were performed using SAS Software (version 9.4). Results Of 2,940 participants in the registry with current contact information, there were 1,384 respondents, reflecting a 47.1% response rate. Characteristics of respondents compared to non-respondents from the IBD registry are shown in Table 1. Respondents are more likely to be female and married. We do not have data on IBD disease duration or therapy use on non-respondents hence we could not compare these variables. Table 1.Comparison of research registry survey respondents and non-respondents.Respondents (n = 1,384)Non-respondents (n = 1,556) P valueMean age, years (SD)58.0 (13.9)57.9 (14.5)0.9553Male gender (%)40.445.9 0.0047 Disease phenotype (%) Crohn’s disease46.949.80.1918 Ulcerative colitis46.745.1— Ileo-anal pouch2.23.0—Mean duration of IBD, years (SD)24.8 (12.8)Not availableNot availableMarital status (%)—— <0.001 Married70.658.2 Common-law8.05.6 Divorced6.06.0 Separated1.83.2 Widowed4.11.4 Never married8.825.4IBD therapy (%) Prednisone3.5Not availableNot available Entocort1.9—— 5-ASA29.4—— Enemas (5-ASA or steroid)2.1—— Azathioprine12.9—— Methotrexate3.7—— Infliximab10.5—— Adalimumab7.4—— Vedolizumab3.9—— Ustekinumab3.5—— Tofacitinib0.1—— Not on any therapy34.9—— Note: Bold= statistical significance at P ≤ 0.05. Comparison of research registry survey respondents and non-respondents. Note: Bold= statistical significance at P ≤ 0.05. Patient characteristics Those who participated in the study were more likely to be female, and to be married. Mean age and IBD phenotype were similar between the two groups. Almost half of the respondents, 46.9% (649) had CD, 46.7% (647) had UC, and 2.2% had an ileoanal pouch. Since the majority of respondents to the survey had either CD or UC (n = 1,296), the majority of the analyses were therefore performed on these people. The mean age was 58.0 (SD 13.9), the age range was 17–91 years old, and 40.6% reported male gender (Table 2). Distribution of age and gender were similar between CD and UC; persons with UC had a shorter duration of disease by a few years on average, compared to those with CD. The majority of respondents (76.8%) had children, with 44.2% of them living at home. Table 2.Characteristics of study participants, stratified by disease subtype.Total(n = 1,296)Crohn’s disease (n = 649)Ulcerative colitis (n = 647)Mean age, years (SD)58.0 (13.90), range57.7 (13.6), range58.3 (14.2), rangeAge, % (n)17–9120–9017–91 17–6464.6 (837)66.1 (429)63.1 (408) 65+35.4 (459(33.9 (220)36.9 (239)Male gender, % (n)40.4 (524)38.8 (252)42.0 (272)Mean duration of IBD, years (SD)24.7 (12.8), range 1–7127.1 (12.9), range 1–7122.4 (12.2), range 1–57Duration of IBD, % (n) 0–1016.2 (198)12.3 (76)20.3 (122) 11–3048.4 (591)43.9 (271)53.2 (320) 30+35.3 (431)43.9 (271)26.6 (160)Medications, % (n) On no IBD therapy32.2 (417)34.7 (225)29.7 (192) 5-ASA therapy (oral, supp, enema)33.3 (432)15.4 (100)51.3 (332) On immune-modifying IBD therapies? (infliximab, adalimumab, vedolizumab, ustekinumab, tofacitinib, azathioprine, methotrexate, or prednisone)38.7 (502)51.6 (335)25.8 (167)Were you on an intravenous therapy for your IBD (i.e., infliximab or vedolizumab)?, % (n) Yes14.9 (193)16.8 (109)13.0 (84)Pre-pandemic employment status Full-time44.1 (572)44.7 (290)43.6 (282) Part-time14.4 (186)13.4 (87)15.3 (99) Full-time student1.4 (18)1.1 (7)1.7 (11) Part-time student0.6 (8)0.6 (4)0.6 (4) Unemployed and looking for work0.9 (11)0.3 (2)1.4 (9) Unemployed and not looking for work1.4 (18)1.7 (11)1.1 (7) Retired38.4 (497)38.2 (248)38.5 (249) Disability4.4 (57)5.7 (37)3.1 (20) Homemaker3.4 (44)3.1 (20)3.7 (24)If you were working pre-pandemic (part- or full-time), were you working during the pandemic? % (n)90.5 (686)89.4 (337)91.6 (349)Of those who were working, during the pandemic, were you working from home?a % (n)49.6 (340)53.1 (179)46.1 (161)Of those who were working, were you considered an essential worker?% (n) Yes65.0 (446)65.3 (220)64.8 (226) Unsure12.2 (84)12.5 (42)12.1 (42)Of those who were working, were you considered a frontline worker? Yes20.6 (141)16.9 (57)24.1 (84) Unsure10.1 (69)9.8 (33)10.3 (36) aDenominator included only included people who were working during the pandemic. Characteristics of study participants, stratified by disease subtype. aDenominator included only included people who were working during the pandemic. A total of 58.5% of respondents were working pre-pandemic, either part-time or full-time, of which 90.5% of those working pre-pandemic were still working during the pandemic. Of those working, almost half (49.6%) were doing so from home. The majority (65.0%) of workers self-identified as an essential worker, and 20.6% of workers self-identified as frontline workers. Eight percent reported losing their job during the pandemic, 11.0% experienced decreased hours, and 6.7% experienced less pay. Because of income loss, 8.8% of respondents had applied for unemployment insurance (EI) during the pandemic. A decrease in total household income was reported by 21.9% of respondents with only a small proportion of 2.5% reporting an increase. In terms of IBD therapy, 32.2% of respondents were not taking any medications for their IBD, while 38.7% were on some form of immune-modifying therapy. CD patients were more likely to be on immune-modifying therapies compared with UC patients, while UC patients were more likely to be on 5-ASA therapies. Of persons using some form of IBD therapy, 10.8% of respondents adjusted their IBD medications on their own, with UC respondents being more likely to do so than CD respondents; 12.6% of respondents had their physician adjust their IBD medications. A mental health disorder, such as depression, anxiety disorder, bipolar disorder, schizophrenia, or PTSD was self-reported by 21.3% of respondents; 78.0% of those indicating a mental-health diagnosis were taking medications for their mental health concerns. Overall, 12.1% of respondents felt they needed help from a mental health professional during the COVID-19 pandemic to date, but only 54.6% of those felt they had adequate access to a mental health professional (Table 3). Table 3.Survey results of study participants, stratified by disease subtype.Total (n = 1,296)Crohn’s disease (n = 649)Ulcerative colitis (n = 647) P value*How many people do you live with? % (n) Live alone13.0 (169)14.6 (95)11.5 (74)0.0980** 149.8 (645)48.5 (315)51.1 (330)— 215.7 (203)16.2 (105)15.2 (98)— 313.9 (180)14.6 (95)13.2 (85)— 4+7.6 (98)6.0 (39)9.1 (59)—Do you have children? % (n) Yes76.8 (995)75.2 (488)78.4 (507)0.1884For those with children: Do your children live with you? % (n) Yes44.2 (440)44.9 (219)43.6 (221)0.7016If your children live with you, were they at home during the pandemic? % (n) Yes76.4 (336)76.7 (168)76.0 (168)0.7877Did you experience the loss of your job during the COVID pandemic? % (n)8.1 (105)8.9 (58)7.3 (47)0.3087Did you experience decreased hours at work because of the COVID pandemic? % (n)11.0 (142)9.7 (63)12.2 (79)0.1556Did you experience less pay due to the COVID-19 pandemic? % (n)6.7 (87)5.4 (35)8.0 (52)0.0598Total household income <$20,0004.1 (53)4.5 (29)3.8 (24)0.6603** $20,000–$49,99918.6 (238)20.0 (129)17.1 (109)— $50,000–$74,99918.1 (232)17.2 (111)19.0 (121)— $75,000–$99,99915.1 (193)15.4 (99)14.8 (94)— $100,000+31.5 (403)30.1 (194)32.8 (209)— Prefer not to answer12.7 (162)12.7 (82)12.6 (80)—Has your total household income (compared to pre-pandemic) Increased2.5 (32)2.5 (16)2.5 (16)0.8201 Decreased21.9 (284)22.7 (147)21.2 (137)— Missing/remained the same75.6 (980)74.9 (486)76.4 (494)—Have you applied for income support (EI) due to loss of income during COVID-19 pandemic?8.8 (114)10.6 (69)7.0 (45)0.0647No answer OR retired/homemaker4.5 (58)4.3 (28)4.6 (30)—I felt general increased stress Completely/somewhat agree73.7 (952)74.6 (484)72.3 (468)0.5818 Neither11.4 (147)11.1 (72)11.6 (75)— Somewhat/completely disagree14.9 (192)13.9 (90)15.8 (102)—I felt increased stress about my IBD Completely/somewhat agree37.7 (486)40.4 (261)34.9 (225)0.0839 Neither23.6 (304)23.5 (152)23.6 (152)— Somewhat/completely disagree38.8 (500)36.1 (233)41.5 (267)—I felt increased stress about my finances Completely/somewhat agree37.5 (482)36.4 (234)38.5 (248) 0.0168 Neither19.3 (248)22.4 (144)16.2 (104)— Somewhat/completely disagree43.3 (557)41.2 (265)45.3 (292)—I felt increased stress about my workplace Completely/somewhat agree44.6 (547)42.7 (262)46.5 (285)0.3264 Neither15.9 (195)17.9 (110)13.9 (85)— Somewhat/completely disagree29.4 (361)29.5 (181)29.4 (180)— Retired9.9 (121)9.8 (60)10.0 (61)— Homemaker0.2 (3)0.2 (1)0.3 (2)—I felt increased stress about my family’s well-being Completely/somewhat agree86.9 (1,113)88.4 (565)85.4 (548)0.2693 Neither5.5 (71)4.9 (31)6.2 (40)— Somewhat/completely disagree7.6 (97)6.7 (43)8.4 (54)—I felt increased stress about accessing my doctor or nurse Completely/somewhat agree46.0 (592)48.4 (310)43.7 (282)0.2116 Neither22.5 (289)21.1 (135)23.8 (154)— Somewhat/completely disagree31.5 (405)30.5 (195)32.5 (210)—I felt increased stress about accessing my prescription IBD meds Completely/somewhat agree21.1 (263)22.9 (143)19.2 (120)0.0752 Neither25.5 (319)26.9 (168)24.2 (151)— Somewhat/completely disagree53.4 (667)50.2 (314)56.6 (353)—I felt there was good access to my doctor or nurse to discuss my IBD Completely/somewhat agree64.2 (821)64.6 (414)63.8 (407)0.4011 Neither21.1 (270)19.5 (125)22.7 (145)— Somewhat/completely disagree10.5 (134)11.2 (72)9.7 (62)— Does not have doctor/nurse4.2 (54)4.7 (30)3.8 (24)—I felt there was good access to my gastroenterologist to discuss my IBD Completely/somewhat agree56.5 (711)60.5 (384)52.4 (327) 0.0083 Neither19.9 (251)17.2 (109)22.8 (142)— Somewhat/completely disagree8.4 (106)9.0 (57)7.9 (49)— Does not have gastroenterologist15.2 (191)13.4 (85)17.0 (106)—I felt there was good access to my doctor or nurse to discuss my non-IBD health care issues Completely/somewhat agree67.2 (863)67.6 (435)66.8 (428)0.2883 Neither16.1 (207)16.0 (103)16.2 (104) Somewhat/completely disagree13.1 (168)12.0 (77)14.2 (91) Does not have doctor/nurse3.7 (47)4.5 (29)2.8 (18)How worried were you about childcare?a Extremely worried15.0 (60)12.9 (26)17.3 (34)0.2365 Somewhat worried20.3 (81)18.3 (37)22.3 (44)— A little worried9.3 (37)8.4 (17)10.2 (20)— Not at all55.4 (221)60.4 (122)50.3 (99)—How worried were you about job stability? b Extremely worried9.5 (102)9.6 (52)9.4 (50)0.8346 Somewhat worried16.6 (178)16.0 (86)17.3 (92)— A little worried18.7 (200)18.0 (97)19.4 (103)— Not at all55.2 (591)56.4 (304)53.9 (287)—How worried were you about financial stability? Extremely worried13.4 (167)13.2 (83)13.5 (84)0.6763 Somewhat worried17.8 (222)18.6 (117)16.9 (105)— A little worried27.9 (349)26.6 (167)29.3 (182)— Not at all41.0 (512)41.7 (262)40.3 (250)—How worried were you about your IBD worsening? Extremely worried8.9 (113)9.4 (60)8.4 (53) 0.0149 Somewhat worried24.7 (313)28.3 (180)21.1 (133)— A little worried26.6 (336)25.6 (163)27.5 (173)— Not at all39.8 (503)36.6 (233)42.9 (270)—How worried were you about your health worsening? Extremely worried13.8 (174)13.5 (86)14.1 (88)0.0915 Somewhat worried27.9 (352)31.0 (197)24.8 (155)— A little worried29.3 (370)28.5 (181)30.2 (189)— Not at all29.0 (366)27.0 (172)31.0 (194)—How worried were you about getting sick from COVID-19? Extremely worried24.5 (311)24.5 (157)24.4 (154)0.3009 Somewhat worried34.0 (432)34.7 (223)33.2 (209)— A little worried30.0 (381)30.8 (198)29.1 (183)— Not at all11.6 (148)10.0 (64)13.3 (84)—How worried were you about a family member getting sick from COVID-19? Extremely worried36.9 (468)36.7 (234)37.1 (234)0.9974 Somewhat worried36.5 (463)36.5 (233)36.5 (230)— A little worried20.2 (256)20.2 (129)20.1 (127)— Not at all36.9 (468)6.6 (42)6.3 (40)—The MOST distressing thing for you during the COVID-19 pandemic Worrying about a family member’s health42.6 (472)40.7 (224)44.5 (248)0.6081c Getting infected with COVID-1932.6 (361)34.0 (187)31.2 (174)— Having my IBD flare11.0 (122)12.0 (66)10.1 (56)— Worrying about finances10.6 (117)10.2 (56)11.0 (61)— Inability to see my doctor3.2 (35)3.1 (17)3.2 (18)—If you were on IBD therapy, did you adjust your own IBD meds on your own? c % (n) Yes10.8 (93)8.23 (34)13.2 (59) 0.0208 Did your doctor adjust your IBD meds? c % (n) Yes12.6 (108)12.7 (53)12.4 (55)0.9181Do you have a mental health diagnosis? (depression, anxiety disorder, bipolar disorder, schizophrenia, or PTSD) % (n) Yes21.3 (275)22.7 (147)19.8 (128)0.2213If you have a mental health diagnosis, are you taking medications for your mental health? % (n) Yes78.0 (213)82.2 (120)73.2 (93)0.0804Did you feel you needed help from a mental health professional during the COVID-19 pandemic?% (n) Yes12.1 (155)13.1 (84)11.0 (71)0.2665If you felt you needed help from a mental health professional, did you feel you had adequate access to a mental health professional during the COVID-19 pandemic? d % (n) Yes54.6 (83)48.2 (40)62.3 (43)0.1021Percentage with elevated health anxiety score, % (n)17.2 (223)17.7 (115)16.7 (108)0.6590Percentage with elevated stress score scale, % (n)63.5 (823)64.6 (419)62.4 (404)0.4533 Notes: Bold= Statistical significance at P ≤ 0.05. aOnly people with children in childcare answered. bOnly answered if they had a job. cPercentage of patients who are on IBD medications (901 patients on IBD therapy, 424 CD people on IBD therapy, and 455 UC people on IBD therapy). dDenominator was people who felt they needed help from a mental health professional. * P value = t test for continuous variables, Fsisher’s exact test for categorical variables. ** P value = Chi-square test. Survey results of study participants, stratified by disease subtype. Notes: Bold= Statistical significance at P ≤ 0.05. aOnly people with children in childcare answered. bOnly answered if they had a job. cPercentage of patients who are on IBD medications (901 patients on IBD therapy, 424 CD people on IBD therapy, and 455 UC people on IBD therapy). dDenominator was people who felt they needed help from a mental health professional. * P value = t test for continuous variables, Fsisher’s exact test for categorical variables. ** P value = Chi-square test. The greatest distress during the pandemic was worry about a family member’s health (42.6%), followed by contracting COVID-19 (32.6%) (noting multiple responses were allowed). Nearly three quarters (73.7%) of respondents completely or somewhat agreed that stress had increased during the COVID-19 pandemic, with 37.7% indicated increased stress about their IBD, 33.6% were extremely or somewhat worried about their IBD worsening (more so in CD than UC), 37.5% felt increased stress about their finances, 44.6% felt increased stress about their workplace, 73.4% were extremely or somewhat worried about a family member getting sick from COVID-19, and 86.9% felt increased stress about their family’s well-being. A total of 41.7% were worried about their health worsening, and 58.5% were extremely or somewhat worried about getting sick from COVID-19. With regard to health care, 46.0% felt increased stress about accessing their doctor or nurse, while 21.1% had increased stress about accessing their prescription IBD medications. Overall, however, 64.2% felt they had good access to their doctor/nurse to discuss their IBD, and 67.2% felt they had good access to discuss their non-IBD healthcare issues. More than half (56.5%) felt they had good access to their gastroenterologist, although that still left a large proportion who did not perceive ready access. Health anxiety Elevated health anxiety was evident for 17.2% of respondents (SHAI > 17). From the multivariable analysis, older age (aOR 0.63, 95% CI 0.42–0.93) was associated with lower odds of health anxiety, while being on immune-modifying therapy (aOR 1.60, 95%CI 1.15–2.22), and the presence of gastrointestinal symptoms (aOR 2.88, 95%CI 2.08–3.99), were associated with increased odds of health anxiety (Table 4). Working from home, having children at home, having fewer work hours due to COVID-19, or being a frontline worker, were not associated with health anxiety. Table 4.Univariable and multivariable predictors of elevated health anxiety (SHAI > 17).Unadjusted odds ratio (95% CI)Adjusted odds ratio (95% CI)Age (65+ vs. 17–64) 0.69 (0.51–0.94) 0.63 (0.42–0.93)Disease duration (years) 11–30 vs. 0–100.88 (0.59–1.32)0.97 (0.63–1.48) 30+ vs. 0–100.68 (0.45–1.05)0.85 (0.52–13.8)IBD phenotype (CD vs. UC)1.08 (0.81–1.43)0.83 (0.60–1.17)Immune-modifying therapy 1.81 (1.36–2.39) 1.60 (1.15–2.22)Presence of GI symptoms 2.97 (2.21–4.00) 2.88 (2.08–3.99)Working from home1.06 (0.77–1.45)0.88 (0.61–1.28)Children at home1.22 (0.89–1.66)0.86 (0.59–1.25)Less hours1.01 (0.64–1.57)0.70 (0.41–1.19)Frontline worker1.08 (0.69–1.68)0.77 (0.46–1.29) Notes: CD = Crohn’s disease; GI = gastrointestinal; IMT = immune-modifying therapy; SHAI = Short health anxiety inventory; UC = Ulcerative colitis. N = 1,211 total observations used in the full model, SHAI > 17 (N = 204).Bold= significant at P < 0.05. Univariable and multivariable predictors of elevated health anxiety (SHAI > 17). Notes: CD = Crohn’s disease; GI = gastrointestinal; IMT = immune-modifying therapy; SHAI = Short health anxiety inventory; UC = Ulcerative colitis. N = 1,211 total observations used in the full model, SHAI > 17 (N = 204). Bold= significant at P < 0.05. Perceived stress Elevated stress was evident for 63.5% of respondents, based on PSS scores > 13. On multivariable analysis, the presence of gastrointestinal symptoms (aOR 2.37, 95% CI 1.83–3.07), working from home (aOR 1.41, 95%CI 1.03–1.92), and being a frontline worker (aOR 1.94, 95%CI 1.22–3.09), were all associated with increased odds of perceived stress (Table 5). In those with a short disease duration of IBD (0–10 years), the odds of perceived stress were much greater for those on immune-modifying therapy, compared to those not on immune-modifying therapy. When disease duration was long (30+ years), IMT had very little impact on the odds of perceived stress. Table 5.Univariate and multivariable predictors of elevated perceived stress (PSS10 > 13).Unadjusted odds ratio (95% CI)Adjusted odds ratio (95% CI)Age (65+ vs. 17–64) 0.59 (0.47–0.74)0.77 (0.57–1.03)Disease duration (years) 11–30 vs. 0–100.73 (0.52–1.04)— 30+ vs. 0–10 0.62 (0.43–0.89)—Disease type (CD vs. UC)1.10 (0.87–1.37)0.92 (0.70–1.19)Immune-modifying therapy (Yes vs. no) 1.56 (1.24–1.97)—GI symptoms (yes vs. no) 2.38 (1.88–3.00) 2.37 (1.83–3.07)Working from home (yes vs. no) 1.62 (1.25–2.10) 1.41 (1.03–1.92)Children at home (yes vs. no) 1.64 (1.27–2.13)1.20 (0.87–1.66)Less hours (yes vs. no) 1.61 (1.11–2.34)1.23 (0.81–1.87)Frontline worker (yes vs. no/unsure) 2.24 (1.50–3.36) 1.94 (1.22–3.09)Disease duration (years) 11–30 vs. 0-10—not on IMT—1.05 (0.64–1.70) 11–30 vs. 0-10—on IMT— 0.52 (0.29–0.93) 30+ vs. 0-10—not on IMT—1.38 (0.83–2.30) 30+ vs. 0-10—on IMT— 0.45 (0.24–0.84) Notes: CD = Crohn’s disease; GI = gastrointestinal; IMT = immune-modifying therapy; PSS = perceived stress scale; UC = ulcerative colitis. N = 1,211 total observations used in the full model, PSS10 > 13 (N = 774).Bold= significant at P < 0.05. Univariate and multivariable predictors of elevated perceived stress (PSS10 > 13). Notes: CD = Crohn’s disease; GI = gastrointestinal; IMT = immune-modifying therapy; PSS = perceived stress scale; UC = ulcerative colitis. N = 1,211 total observations used in the full model, PSS10 > 13 (N = 774). Bold= significant at P < 0.05. Discussion In this population-based sample of adults with IBD during the second wave of the COVID-19 pandemic, one in five reported a pre-existing mental health diagnosis, and approximately three-quarters of respondents reported increased stress. For most, stress was focused on family well-being increased during the pandemic, with increased stress also evident regarding their work, financial stability, and their IBD. While almost half acknowledged more stress about accessing their health care provider during the pandemic, close to two-thirds felt they were able to access their health care provider as needed, although only half felt they had good access specifically to their gastroenterologist. While these findings would suggest there was still a significant minority who did not have the needed access for their health care concerns, compared with information we had available pre-COVID regarding access, there may have been an improvement. That is, in a study accessing participants from this registry undertaken in 2017, 42% reported having good access to their gastroenterologist by telephone when needed,16 whereas 56% reported good access at this point in the pandemic. Physician access could have improved, as there was increased availability of telemedicine options fairly early in the pandemic in this jurisdiction. However, nearly half of respondents with mental health issues felt they did not have adequate access to a mental health professional. It is well established that persons with IBD have significantly higher rates of depression and anxiety than the general population and that mental health symptoms exacerbate disease symptoms and impair quality of life.17,18 A study of older adults with IBD (≥65 years old) found 22.6% met the criteria for major depression, were more likely to be on corticosteroids and had worse medication adherence, compared to those without depression.19 In our study, we found that older age was associated with a decreased likelihood of health anxiety or of elevated stress, though this was only statistically significant on univariate analysis. It is well known that older people are at increased risk of severe disease and death with COVID-19,20 with one meta-analysis calculating a hazard ratio of 2.61 for mortality in older people.21 Despite the publicity surrounding the risk of COVID-19 to the elderly as well as for those with underlying conditions, older people had decreased health anxiety and perceived stress in our study. Similarly, a Norwegian survey study found that persons with IBD (more than 95% on biologic therapy) who were less than 50 had more concerns about their treatment in the context of COVID-19 than those over 50.22 A national Australian survey of individuals with IBD during the COVID-19 pandemic revealed younger age was associated with significant stress, anxiety, and/or depression.9 It is known that mental health disorders decrease as people age.23 Nearly 40% of participants were on some form of immune-modifying therapy, and this was associated with increased odds of health anxiety and perceived stress. Being on immune-modifying therapy by definition means these people either have moderate-to-severe disease or have mild disease but have failed prior therapies. While one may think that this experience would lead to an increase in their resilience, persons on immune-modifying therapies may have perceived themselves to be at increased risk of contracting COVID-19, and been concerned that in needing more care, they might not have ready access to timely care. Longer IBD disease duration was associated with decreased odds of perceived stress, including those on immune-modifying therapies. It is possible that the longer one has IBD, they develop resilience and coping mechanisms and are better able to handle the stress of COVID-19. It has been shown that increased resilience is associated with lower disease activity and improved quality-of-life,24 as well as decreased rates of anxiety and depression.25 Persons with IBD who have active disease can feel isolated, although they can still have good social support, comparable to people without IBD.26 Of the respondents who were on some form of IBD therapy, 10.8% adjusted therapy on their own, and 21.1% of respondents felt increased stress accessing their IBD medications. An observational survey in Italy during the COVID-19 pandemic revealed that 16.3% of respondents discontinued therapy on their own, while 37.4% delayed therapy, mostly related to a fear of COVID-19.27 It’s unknown what led to these autonomous changes, perhaps the thought that decreasing one’s own therapy would lessen one’s risk of contracting COVID-19, though 20.3% of respondents felt increased stress about accessing their IBD medications. Unfortunately, we do not know what the base rates in our population were for self-adjusting therapy in a non-pandemic era. A large study assessing healthcare claims data in the United States showed a reduction in colonoscopies and initiation/switching of IBD therapies early on in the COVID-19 pandemic, while telehealth services use increased.3 Whether a decrease in healthcare utilization early on in the pandemic led to the worsening of one’s disease status is not yet known. This decrease in procedures, or perhaps the fear of not getting the care one should receive, could have led to increased anxiety or perceived stress. A small Dutch survey study (n = 63), reported that lockdown-related social isolation and fear of COVID-19 were associated with clinical activity of CD.28 Since high perceived stress is significantly associated with symptom flares,7 it will be of interest to determine if participants in our study with high perceived stress ultimately did have increased disease activity.29 In the future we will be studying our cohort’s health care utilization including colonoscopies and their ultimate health IBD health outcomes. Of course, people without IBD also experienced elevated health anxiety and stress during the pandemic. Some expect long-term mental health consequences throughout the population secondary to the pandemic, especially from prolonged lockdown measures and social isolation.30 A Canadian survey of 3,000 people during the first wave of the pandemic revealed that 37.4% of respondents had worse mental health at the time of the survey compared with pre-pandemic, with 41.9% of respondents who quarantined reporting worsening mental health symptoms.31 A meta-analysis revealed symptoms of psychological distress, depression, and anxiety were all found to be higher during the first wave of the COVID-19 pandemic.32 Our study has many strengths, including an excellent response rate (47.1%) of a population-based sample. The responses were during the second wave of the COVID-19 pandemic, before vaccines were available, and while key information about this novel virus was still being discovered. People in this region, similar to other regions and countries, experienced frequent government-mandated lockdowns and restrictions on public and private gatherings. Hence, these data reflect a specific, early time in the pandemic and highlight some of the needs of persons with IBD during a pandemic such as better access to their gastroenterologist and mental health professionals. Our study also has some limitations. Our cohort was older with a modestly higher proportion of women. The study design was cross-sectional, which does not allow for change comparisons from pre-pandemic levels of health anxiety and stress, or potential effect on IBD disease state. A major limitation is our study did not have a comparison group of adults without IBD to compare rates of elevated health anxiety and stress in the general population in the context of the pandemic. While most people, even those without IBD, had an increase in clinically significant mental health symptoms, we feel our results highlight the stressors and anxieties that people with IBD encountered during the pandemic, and this may help to identify areas to target in the future. Persons with IBD are already at increased risk of mental health disorders compared with the general population. It is possible that increased resilience, and experience dealing with a chronic disease over years prepared some for the rigors of dealing with COVID-19. More research is needed to assess if heightened levels of stress or health anxiety lead to worsening disease activity, and further if the delay in health care aspects such as colonoscopies and surgeries or the perceived decreased access to health care professionals for some with IBD during strict lockdowns will have detrimentally impacted the disease course for persons with IBD. The importance of understanding the experiences of persons with IBD during the COVID-19 pandemic can guide the current response to ongoing needs, especially if the needs have increased overall for this patient population, in addition to considering changes in our approach to clinical care during future waves of the current or other pandemics. Supplementary Material Click here for additional data file. Contributor Information Seth R Shaffer, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, C4-820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Gia L Jackson, University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Sydney Chochinov, University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Casandra Dolovich, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, C4-820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Lesley A Graff, University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, PZ-350 820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Renée El-Gabalawy, University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, PZ-350 820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Souradet Yuh-Nan Shaw, University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Harminder Singh, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, C4-820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Charles N Bernstein, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, C4-820 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada; University of Manitoba IBD Clinical and Research Centre, University of Manitoba, MS-783 Sherbrook St Winnipeg, Manitoba, R3A1R9, Canada. Author contributions Seth R. Shaffer (study concept and design, analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis), Gia L. Jackson (acquisition of data), Sydney Chochinov (acquisition of data), Casanadra Dolovich (analysis and interpretation of data; critical revision of the manuscript for important intellectual content; statistical analysis; technical, or material support; study supervision), Lesley Graff (study concept and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content), Renee E.L. Gabalawy (analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content), Souradet Shaw (study concept and design; acquisition of data; analysis and interpretation of data; critical revision of the manuscript for important intellectual content), Harminder Singh (analysis and interpretation of data; critical revision of the manuscript for important intellectual content; technical, or material support), and Charles N. Bernstein (acquisition of funding, study concept, and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; technical, or material support; study supervision) Funding This study was funded by unrestricted grants from Abbvie Canada, Pfizer Canada, and Sandoz Canada. Conflict of interest statement Dr. Shaffer has served on advisory boards or consulted with Takeda Canada, Janssen Canada, and Pfizer Canada. Dr. Bernstein has consulted to or served on advisory boards for Abbvie Canada, Amgen Canada, Bristol Myers Squibb Canada, JAMP Pharmaceuticals, Janssen Canada, Pfizer Canada, Sandoz Canada, Takeda, and has received unrestricted educational grants from Abbvie Canada, Janssen Canada, Pfizer Canada, Bristol Myers Squibb Canada, and Takeda Canada. He has been on the speaker’s bureau of Abbvie Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. He has received research grants from Abbvie Canada, Amgen Canada, Pfizer Canada, and Sandoz Canada, and contract grants from Janssen. Dr Graff has consulted to Roche Canada. Dr. Singh has been on advisory boards or consulted Amgen Canada, Roche Canada, Sandoz Canada, Takeda Canada, and Guardant Health, Inc. The other authors have no conflicts of interest to declare. Data availability statement The data underlying this article are available in the article and in its online supplementary material. References Associated Data Supplementary Materials Click here for additional data file. Data Availability Statement The data underlying this article are available in the article and in its online supplementary material.